Suppression of coronary vasculitis in a murine model of Kawasaki disease using an angiogenesis inhibitor

Clinical Immunology

Volumn 90, Issue 1, 1999, Pages 147-151

  Brahn, E ^a   Lehman, T J A ^b   Peacock, D J ^a   Tang, C ^a   Banquerigo, M L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AGM 1470; Angiogenesis inhibition; Kawasaki vasculitis; Lactobacillus casei; TNP 470; Vasculitis therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LACTOBACILLUS CASEI; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULITIS;

EID: 0032951488     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1998.4645     Document Type: Article

References (15)

1. Kawasaki T., Kosaki F., Okawa S., Shigematsu I., Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 543:1974;271-276.
2. Newburger W., Sundel R. P. Kawasaki disease and its cardiac sequelae. Hosp. Practice. 28:1993;51-66.
3. Kato H., Ichinose E., Yoshioka F., Takechi T., Matsunaga S., Suzuki K., Rikitake N. Fate of coronary aneurysms in Kawasaki disease: Serial coronary angiography and long term followup study. Am. J. Cardiol. 49:1982;1758-1766.
4. Tanaka N., Sekimoto K., Naoe S. Kawasaki disease. Relationship of infantile periarteritis nodosa. Arch. Pathol. Lab. Med. 100:1976;81-86.
5. Lehman T. J. A., Walker S. M., Mahnovski V., McCurdy D. Coronary arteritis in mice following the systemic injection of group BLactobacillus casei. Arthritis Rheum. 28:1985;652-659.
6. Katz A. R., Lehman T. J. A. Lactobacillus casei. Handbook of Animal Models for the Rheumatic Diseases. 1988;CRC Press, Boca Raton. p. 219-225.
7. Jones M. M., Vivado A. K., Landas S., Waldschmidt T. J. Immune regulation inL. casei. Arthritis Rheum. 36:1993;S277.
8. Barthori J. M., Shulman S. T., Lehman T. J. A., Myones B. L. Human intravenous IgG inhibits the development of coronary arteritis in a murine model. Arthritis Rheum. 36:1993;S61.
9. Newburger J. W., Takahashi M., Beiser A. S. A single intravenous infusion of gammaglobulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 324:1991;1633-1639.
10. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature. 348:1990;555-557.
11. Peacock D. J., Banquerigo M. L., Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J. Exp. Med. 175:1992;1135-1138.
12. Oliver S. J., Banquerigo M. L., Brahn E. Suppression of collagen induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, Taxol. Cell. Immunol. 157:1994;291-299.
13. Peacock D. J., Banquerigo M. L., Brahn E. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell. Immunol. 160:1995;178-187.
14. Oliver S. J., Cheng T. P., Banquerigo M. L., Brahn E. Suppression of collagen induced arthritis with an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: Reduction of vascular endothelial growth factor (VEGF). Cell. Immunol. 166:1995;196-206.
15. Antoine N., Greimers R., De Roanne C., Kusaka M., Heinen E., Simar L. J., Castronovo V. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res. 54:1994;2073-2076.